Download MendeleyDiscovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.
Haffner, C.D., Charnley, A.K., Aquino, C.J., Casillas, L., Convery, M.A., Cox, J.A., Elban, M.A., Goodwin, N.C., Gough, P.J., Haile, P.A., Hughes, T.V., Knapp-Reed, B., Kreatsoulas, C., Lakdawala, A.S., Li, H., Lian, Y., Lipshutz, D., Mehlmann, J.F., Ouellette, M., Romano, J., Shewchuk, L., Shu, A., Votta, B.J., Zhou, H., Bertin, J., Marquis, R.W.(2019) ACS Med Chem Lett 10: 1518-1523
- PubMed: 31749904
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00141
- Primary Citation of Related Structures:
6SZE, 6SZJ, 6UL8 - PubMed Abstract:
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.
Organizational Affiliation:
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States.
